The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Introduction The global bioconjugation market is witnessing robust growth, primarily driven by the expanding demand for targeted therapies and ...

The promise of mRNA technology seemed boundless after the success of the coronavirus vaccines, but Robert F. Kennedy Jr. has singled it out for scrutiny, clouding its prospects.